No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]
, 2012 Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Ferdinand Bohmann +27 more
core +2 more sources
Therapeutic potential of small molecules that block receptor-induced Kv7/M-current suppression in neuroprotection, seizures, and pain. [PDF]
Br J PharmacolReceptor‐induced Kv7/M‐current suppression increases neuronal activity and contributes to pathology of several conditions. A new class of Kv7 modulators identified in this study attenuates M‐current suppression and shows therapeutic effects. Abstract Background and Purpose Neuronal Kv7 channels generate low voltage–gated potassium currents known as the
Kim YW +5 more
europepmc +2 more sources
Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]
, 2013 We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Baas, Horst +7 more
core +1 more source
Dose tailoring of dabigatran etexilate: obvious or excessive? [PDF]
, 2015 Introduction: Dabigatran etexilate is used for preventing blood clots and tends to replace older anticoagulants in many of their indications. However, the ‘one dose fits all’ policy is subject to criticism.
Mullier, François +3 more
core +1 more source
Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines [PDF]
Journal of Primary Health Care, 2020 INTRODUCTIONDabigatran etexilate has become widely used in New Zealand, but information relating to when renal function monitoring is being undertaken is lacking.
Alesha J. Smith +3 more
doaj
Preclinical testing of dabigatran in trypsin-dependent pancreatitis
JCI Insight, 2022 Pancreatitis, the inflammatory disorder of the pancreas, has no specific therapy. Genetic, biochemical, and animal model studies revealed that trypsin plays a central role in the onset and progression of pancreatitis.
Zsófia Gabriella Pesei +5 more
doaj +1 more source
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. [PDF]
Blood, 2020 This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention.
Brandão LR +18 more
europepmc +2 more sources
Pharmacogenetics of dabigatran etexilate interindividual variability [PDF]
, 2016 Introduction Dabigatran etexilate is given in fixed doses without coagulation monitoring for the prevention of blood clots in at risk adults. A high inter-individual variability in blood concentrations of the active metabolite of dabigatran has been ...
Vecchione, Gennaro +9 more
core +1 more source
Use of idarucizumab for emergency surgery in patients taking dabigatran
Атеротромбоз, 2022 This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova +5 more
doaj +1 more source
Case Reports in Critical Care, 2015 The oral anticoagulant dabigatran etexilate can be a challenge when patients need acute surgery. Sepsis and acute renal failure exacerbate the anticoagulant effect.
Rikke Ebenhard Højland +2 more
doaj +1 more source